ADC Capacity Updates
-
Simtra BioPharma Solutions Capacity Update October 2024: ADC
10/21/2024
We've expanded our U.S. and Germany sites to offer end-to-end services for product development, clinical and commercial fill/finish, and ADC conjugation and purification by 2025.
-
Mycenax Capacity Update October 2024: ADC
10/21/2024
Partner with us for full-service ADC development and production, from feasibility to GMP manufacturing, with industry-leading standards and flexible capacities.
-
KBI Biologics Capacity Update October 2024: ADC
10/21/2024
This presentation underscores the essential role of comprehensive characterization in ensuring that ADCs not only meet regulatory standards but also achieve therapeutic goals.
-
JOINN Biologics Capacity Update October 2024: ADC
10/21/2024
Leverage our flexible solutions and access to proprietary CHO-K1 cell lines in our state-of-the-art cGMP suites equipped with both single-use and traditional stainless steel bioreactors to support your complex biologics needs.
-
Catalent Capacity Update October 2024: ADC
10/21/2024
Advance ADC development with the SMARTag® Platform, combining precision bioconjugation and a linker-payload library to enhance the therapeutic index and accelerate timelines.
-
AGC Biologics Capacity Update October 2024: ADC
10/21/2024
Streamline your ADC project with the Proveo alliance, offering seamless, end-to-end support across antibody production, bioconjugation, and aseptic fill.
-
Abzena Capacity Update October 2024: ADC
10/21/2024
Leverage our integrated CRO and CDMO services for the development and manufacturing of complex biologics, bioconjugates, and ADCs, ensuring high-quality products and data packages that meet regulatory requirements.